← Eichor
Condition: Burkitt Lymphoma Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Burkitt Lymphoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Study of YK012 in B-cell Acute Lymphoblastic Leukemia
Phase 1/Phase 2 · 12 location(s) · Excyte Biopharma Ltd · NCT06580301Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers
Phase 2 · 10 location(s) · Fred Hutchinson Cancer Center · NCT03779854Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumo
Phase 1/Phase 2 · 71 location(s) · Merck Sharp & Dohme LLC · NCT06395103Newly-diagnosed Low Risk Pediatric B-cell ALL Protocol
Phase 2/Phase 3 · 27 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT06882057Combination of Inaticabtagene Autoleucel With Autologous Hematopoietic Stem Cell Transplantation for Adolescents or Adul
Phase 2 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT06608732Safety, Tolerability, and Pharmacokinetics of Donor-derived CD19 CAR Therapy Bridged Allo-HSCT and Sequential Donor-deri
Phase 1 · 1 location(s) · Beijing GoBroad Hospital · NCT06326008A Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric)
Phase 1/Phase 2 · 9 location(s) · Juventas Cell Therapy Ltd. · NCT05667506Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
Phase 2 · 1 location(s) · Masonic Cancer Center, University of Minnesota · NCT03314974ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML
Phase 1 · 4 location(s) · Marlise Luskin, MD · NCT03595917NexCAR19 (Talikabtagene Autoleucel) in Relapsed/Refractory B-Cell Malignancies (NexCAR19)
Phase 2/Phase 3 · 4 location(s) · Health Institutes of Turkey · NCT07502118Clinical Study of Hospital-manufactured CD19 CAR-T in Children and Adolescents With Acute Lymphoblastic Leukemia
Phase 1 · 1 location(s) · Seoul National University Hospital · NCT05210907Targeted CD22/CD19 CAR-T Therapy for Consolidation in Standard-Risk B-ALL
Phase 1/Phase 2 · 1 location(s) · Liping Dou · NCT07575919Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies
Phase 1/Phase 2 · 1 location(s) · Beijing Biotech · NCT07523555Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
Phase 1/Phase 2 · 1 location(s) · National Cancer Institute (NCI) · NCT032236103'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
Phase N/A · 1 location(s) · Barbara Ann Karmanos Cancer Institute · NCT00935090CD19-CD22-Bispecific Chimeric Antigen Receptor (CAR) T Cell Therapy for Pediatric Patients With Acute Lymphoblastic Leuk
Phase 1 · 1 location(s) · St. Jude Children's Research Hospital · NCT06777979Long-term Follow-up Study of Patients Receiving CAR-T Cells
Phase N/A · 1 location(s) · Medical College of Wisconsin · NCT03375619The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
Phase 1/Phase 2 · 11 location(s) · AVM Biotechnology Inc · NCT04329728Combination of an Anti-PD1 Antibody With Tisagenlecleucel Reinfusion in Children, Adolescents and Young Adults With Acut
Phase 1/Phase 2 · 13 location(s) · Assistance Publique - Hôpitaux de Paris · NCT05310591Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual C
Phase 2 · 113 location(s) · National Cancer Institute (NCI) · NCT06317662A Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of B019 Injection in Subjects With Relap
Phase 1 · 8 location(s) · Shanghai Pharmaceutical Group Biological Therapy Technology · NCT06927466Study of Nutrition and Exercise in Adults Hospitalized for Treatment of Acute Lymphoblastic Leukemia (ALL)
NA · 1 location(s) · University of Chicago · NCT06785324JY231 (JY231) Injection for the Treatment of B-cell Acute Lymphoblastic Leukemia (B-ALL)
EARLY_Phase 1 · 1 location(s) · 920th Hospital of Joint Logistics Support Force of People's · NCT06514768Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT02877303CIK Cell Therapy for Relapsed or Refractory Acute B-Lymphoblastic Leukemia: Prognostic Impact on Patients With Early CAR
NA · 1 location(s) · Beijing GoBroad Hospital · NCT06389305Bridging Allogeneic Hematopoietic Stem Cell Transplantation or Not After CD19 CAR - T (S1904) Cell Therapy for r/r B-cel
NA · 1 location(s) · Peking University People's Hospital · NCT06581081JY231(JY231) Injection for the Treatment of Relapsed/Refractory B Cell Lymphoma/ Leukemia
NA · 1 location(s) · Shenzhen Genocury Biotech Co., Ltd. · NCT06890065JY231(JY231) Injection for the Treatment of Relapsed/Refractory B Cell Lymphoma/ Leukemia
NA · 1 location(s) · Affiliated Hospital of Guangdong Medical University · NCT06940960Immunotherapy in Lymphoma
Phase N/A · 2 location(s) · Sung-Soo Park · NCT06796517Study of Inotuzumab Ozogamicin, Venetoclax, and Dexamethasone for Relapsed B-cell ALL
Phase 1 · 1 location(s) · Children's Hospital Medical Center, Cincinnati · NCT06863259
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.